Due to its unique therapeutic potential to selectively modulate T cell responses in GvHD but not in anti-leukemia effects, as well as lipid-cholesterol metabolism by regulating both CETP and CB1, BI-5756 will also provide broader implications beyond allo-HCT, including solid organ transplant rejection and other inflammatory diseases. Here, CETP is linked to leukemia.